Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Nature. 2006 Apr 27;440(7088):1123.

    Gene therapy: therapeutic gene causing lymphoma.

    Source

    Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, California 92037, USA.

    Abstract

    The development of T-cell leukaemia following the otherwise successful treatment of three patients with X-linked severe combined immune deficiency (X-SCID) in gene-therapy trials using haematopoietic stem cells has led to a re-evaluation of this approach. Using a mouse model for gene therapy of X-SCID, we find that the corrective therapeutic gene IL2RG itself can act as a contributor to the genesis of T-cell lymphomas, with one-third of animals being affected. Gene-therapy trials for X-SCID, which have been based on the assumption that IL2RG is minimally oncogenic, may therefore pose some risk to patients.

    Comment in

    • Gene therapy: is IL2RG oncogenic in T-cell development? [Nature. 2006]
    • Gene therapy: X-SCID transgene leukaemogenicity. [Nature. 2006]
    PMID:
    16641981
    [PubMed - indexed for MEDLINE]

    LinkOut - more resources

    Full Text Sources

    Other Literature Sources

    Education

    Medical

    Molecular Biology Databases

    Research Materials

    Miscellaneous

      Supplemental Content

      Icon for Nature Publishing Group

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk